
    
      Inclusion Criteria:

        1. Histological or cytological diagnosis of non-small cell lung cancer.

        2. Cytological diagnosis of malignant pleural or pericardial effusion (MPE)

        3. Symptomatic MPE evaluated by researchers

        4. Unsuitable for or reject systemic therapy of tumor

        5. Continuous TKI treatment after TKI-resistance

        6. Estimated survival of more than 3 months. 7.18 years or older

      Exclusion Criteria:

        1. Current or recent (within 10 days prior to treatment) use the full amount of inhibition
           of platelet function, anticoagulants or thrombolytic therapy, which allows prophylactic
           anticoagulants

        2. Be allergic to bevacizumab

        3. Pregnant or lactating woman

        4. Pleural or pericardial infection
    
  